Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > AKBA Akebia Therapeutics > Detailed Quotes

AKBA Akebia Therapeutics

0.305
-0.003-0.97%
Trading Session 09/27 12:45 ET
High
0.333
Open
0.330
Turnover
374.79K
Low
0.305
Pre Close
0.308
Volume
1.18M
Market Cap
56.09M
P/E(TTM)
Loss
52wk High
3.350
Shares
183.85M
P/E(Static)
Loss
52wk Low
0.300
Float Cap
54.67M
Bid/Ask %
99.59%
Historical High
31.000
Shs Float
179.20M
Volume Ratio
1.62
Historical Low
0.300
Dividend TTM
--
Div Yield TTM
--
P/B
0.90
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.66%
Amplitude
8.93%
Avg Price
0.318
Lot Size
1
Float Cap
54.67M
Bid/Ask %
99.59%
Historical High
31.000
Shs Float
179.20M
Volume Ratio
1.62
Historical Low
0.300
Dividend TTM
--
P/B
0.90
Dividend LFY
--
Turnover Ratio
0.66%
Amplitude
8.93%
Avg Price
0.318
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
CEO: Mr. John P. Butler
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...